Univariate analysis of predictors of survival since initiation of treatment with infliximab
. | No. . | No. alive . | No. HR . | 95% CI* . | P* . |
|---|---|---|---|---|---|
| Response | 0.1-1.2 | .1 | |||
| CR/PR | 14 | 7 | 0.4 | ||
| Other | 7 | 1 | 1.0 | ||
| Age, y | 0.2-1.8 | .4 | |||
| 47 and younger | 10 | 3 | 1.0 | ||
| Older than 47 | 11 | 5 | 0.6 | ||
| Sex | 0.4-3.0 | .8 | |||
| Male | 14 | 6 | 1.0 | ||
| Female | 7 | 2 | 1.1 | ||
| Acute GVH grade | 0.5-6.6 | .4 | |||
| 1-2 | 17 | 7 | 1.0 | ||
| 3-4 | 4 | 1 | 1.8 | ||
| Donor type | 0.3-2.6 | .8 | |||
| HLA-matched sibling | 11 | 4 | 0.9 | ||
| MM rel/MUD | 10 | 4 | 1.0 |
. | No. . | No. alive . | No. HR . | 95% CI* . | P* . |
|---|---|---|---|---|---|
| Response | 0.1-1.2 | .1 | |||
| CR/PR | 14 | 7 | 0.4 | ||
| Other | 7 | 1 | 1.0 | ||
| Age, y | 0.2-1.8 | .4 | |||
| 47 and younger | 10 | 3 | 1.0 | ||
| Older than 47 | 11 | 5 | 0.6 | ||
| Sex | 0.4-3.0 | .8 | |||
| Male | 14 | 6 | 1.0 | ||
| Female | 7 | 2 | 1.1 | ||
| Acute GVH grade | 0.5-6.6 | .4 | |||
| 1-2 | 17 | 7 | 1.0 | ||
| 3-4 | 4 | 1 | 1.8 | ||
| Donor type | 0.3-2.6 | .8 | |||
| HLA-matched sibling | 11 | 4 | 0.9 | ||
| MM rel/MUD | 10 | 4 | 1.0 |
MM rel/MUD indicates mismatched related/matched-unrelated donor.
95% Cl and P values refer to HR.